# AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

> **NCT06511895** · PHASE2 · COMPLETED · sponsor: **Dizal Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** AZD4205

## Key facts

- **NCT ID:** NCT06511895
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-31
- **Primary completion:** 2025-10-17
- **Final completion:** 2025-10-17
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06511895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06511895, "AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06511895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*